title: An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up.
abstract: In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI-20%, 30%] and 2% [95% CI-26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.
authors.affiliation: Medical Research Council Laboratories, Fajara, The Gambia.
authors.forename: K A
authors.initials: KA
authors.lastname: Bojang
authors.forename: S K
authors.initials: SK
authors.lastname: Obaro
authors.forename: U
authors.initials: U
authors.lastname: D'Alessandro
authors.forename: S
authors.initials: S
authors.lastname: Bennett
authors.forename: P
authors.initials: P
authors.lastname: Langerock
authors.forename: G A
authors.initials: GA
authors.lastname: Targett
authors.forename: B M
authors.initials: BM
authors.lastname: Greenwood
mesh_terms: D000818:Animals; D005260:Female; D005500:Follow-Up Studies; D005714:Gambia; D006801:Humans; D007223:Infant; D017780:Malaria Vaccines / Q000627:therapeutic use*; D016778:Malaria, Falciparum / Q000517:prevention & control*; D008297:Male; D010963:Plasmodium falciparum; D015800:Protozoan Proteins; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000627:therapeutic use
chemical_list: D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic